New options on the horizon for nononcogene addicted non-small-cell lung cancer

The treatment of non-small-cell lung cancer (NSCLC) has historically been based on platinum doublets- and taxan-based chemotherapy in the first- and second-line therapy, respectively. Although new agents have emerged for patients with driver mutations, treatment options for nononcogene addicted NSCL...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2018-06, Vol.14 (13s), p.19-28
Main Authors: Paglialunga, Luca, Ricciardi, Serena, D'Arcangelo, Manolo
Format: Article
Language:English
Subjects:
Algorithms
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomarkers, Tumor
Cancer therapies
Carcinoma, Non-Small-Cell Lung - etiology
Carcinoma, Non-Small-Cell Lung - mortality
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Non-Small-Cell Lung - therapy
Chemotherapy
Clinical medicine
Clinical trials
Combined Modality Therapy
Disease Management
Humans
immune checkpoint inhibitors
Immunotherapy
Kinases
Lung cancer
Lung Neoplasms - etiology
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Lung Neoplasms - therapy
Medical research
Metastasis
Molecular Targeted Therapy
Monoclonal antibodies
Mutation
Neoplasm Staging
NSCLC
Retreatment
Systematic review
therapeutic algorithm
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The treatment of non-small-cell lung cancer (NSCLC) has historically been based on platinum doublets- and taxan-based chemotherapy in the first- and second-line therapy, respectively. Although new agents have emerged for patients with driver mutations, treatment options for nononcogene addicted NSCLC have not changed for years. However, the last 5 years have seen the approval and introduction of new biological agents, such as immune checkpoint inhibitors and antiangiogenic drugs. The aim of this review is to give readers an update on the news in the treatment of nononcogene addicted NSCLC. As more and more therapeutic options are now available, we will delineate a potential therapeutic algorithm for the optimization of daily life treatment choice of NSCLC patients.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2018-0096